Back to School: How biopharma can reboot drug development. Access exclusive analysis here

NovaDel, Suda deal

NovaDel will sell its NovaMist sublingual delivery technology along with other assets to Suda for an upfront payment of $400,000 plus 50 million shares of Suda

Read the full 267 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE